[{"id":"2a13790b-df30-4d16-94bd-4e9b80cce1c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098210","created_at":"2021-10-28T17:56:20.511Z","updated_at":"2024-07-02T16:35:22.189Z","phase":"Phase 1","brief_title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer","source_id_and_acronym":"NCT05098210","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • BRAF • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • BRAF • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"}]